2019 American Society of Hematology Annual Meeting*

Initial results from ongoing phase II study suggest clinical activity of luspatercept in patients with MF-associated anemia.

Venetoclax alone or in combination with azacitidine was well tolerated in patients with relapsed/refractory MDS, with combination therapy achieving an ORR of 40% and estimated 12-month OS of 65%.

In patients with TP53-mutant MDS/AML, APR-246 plus azacitidine was active and generally well tolerated.

Interim findings demonstrate that APR-246 yields a high CR rate when combined with azacitidine in patients with MDS or AML with TP53 mutations.

Longer-term analysis of the MEDALIST study showed that more luspatercept-treated patients attained transfusion independence for ≥ 8 weeks any time during therapy compared with placebo.